上海交通大学学报（医学版）

›› 2011, Vol. 31 ›› Issue (6): 797-.doi: 10.3969/j.issn.1674-8115.2011.06.025

• 论著（临床研究） • 上一篇    下一篇

抗瘤增效方减轻晚期非小细胞肺癌化疗不良反应的时效研究

祝利民, 张 晖, 周 浩, 潘传芳, 沈克平, 徐振晔   

  1. 上海中医药大学附属龙华医院肿瘤科, 上海 200032
  • 出版日期:2011-06-28 发布日期:2011-06-27
  • 作者简介:祝利民（1977—）, 女, 主治医师, 硕士；电子信箱: zhulimin2000@sina.com。
  • 基金资助:

    上海市重点学科建设项目（Y0302）

Time-effect relationship of Kangliu Zengxiao Decoction in reducing chemotherapy-associated adverse reactions in patients with advanced non-small cell lung cancer

ZHU Li-min, ZHANG Hui, ZHOU Hao, PAN Chuan-fang, SHEN Ke-ping, XU Zhen-ye   

  1. Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
  • Online:2011-06-28 Published:2011-06-27
  • Supported by:

    Shanghai Leading Academic Discipline Project, Y0302

PDF (PC)

1658

摘要：

目的 观察不同给药时间对抗瘤增效方减轻晚期非小细胞肺癌化疗不良反应的影响。方法 选择124例非小细胞肺癌患者，随机分为提前10、5和0 d应用抗瘤增效方+化疗组（A、B、C组）以及单纯化疗组（D组）。比较4组患者的中医症状及证候、生存质量、免疫功能以及骨髓抑制、肝肾功能、消化道等不良反应的差异。结果 A组患者治疗后的中医症状（神疲乏力、腰酸腿软）和证候改善率均明显优于B、C、D组（P<0.05）；A组治疗后CD3、CD4百分比和CD4/CD8比值均较B、C、D组明显升高（P<0.05）；生存质量改善率也明显优于D组（P<0.01）。不良反应方面，A组的骨髓抑制（白细胞和中性粒细胞降低）、肝脏毒性、恶心呕吐的发生率均明显低于D组（P<0.05），其他不良反应发生率组间比较差异均无统计学意义（P>0.05）。结论 抗瘤增效方在化疗前10 d应用对减轻晚期非小细胞肺癌化疗不良反应、提高患者生存质量及免疫功能等方面较化疗前5 d及化疗同时运用具有更好的效果。

关键词: 抗瘤增效方, 非小细胞肺癌, 化疗, 时效关系

Abstract:

Objective To observe the time-effect relationship of Kangliu Zengxiao Decoction in reducing chemotherapy-associated adverse reactions in patients with advanced non-small cell lung cancer. Methods One hundred and twenty-four patients with advanced non-small cell lung cancer were randomly divided into four groups. Patients in group A, group B and group C were treated with Kangliu Zengxiao Decoction 10 d, 5 d and 0 d before chemotherapy respectively, and those in group D received chemotherapy only. The main clinical symptoms, quality of life, immune function and adverse reactions of myelosuppression, liver and kidney function, and digestive system were compared among groups. Results The improvement rates of clinical symptoms (fatigue, aching lumbus and limp legs), the percentages of CD3 and CD4, and the ratio of  CD4 to CD8 in group A were significantly higher than those in group B, group C and group D (P<0.05), and the improvement rate of quality of life in group A was significantly higher than that in group D (P<0.01). The incidences of myelosuppression (decrease in numbers of white cells and neutrophils), hepatotoxicity, nausea and vomiting in group A were significantly lower than those in group D (P<0.05), while there was no significant difference in the incidences of the other adverse reactions among groups (P>0.05）. Conclusion Application of Kangliu Zengxiao Decoction 10 d before chemotherapy may gain better results in reducing adverse reactions of chemotherapy, improving quality of life and immune function than administration 5 d and 0 d before chemotherapy in patients with advanced non-small cell lung cancer.

Key words: Kangliu Zengxiao Decoction, non-small cell lung cancer, chemotherapy, time-effect relationship